On March 15, 2023 OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, reported a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida (Press release, OncoResponse, MAR 15, 2023, View Source [SID1234628838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Title: Discovery and preclinical characterization of dual antagonist antibodies targeting both LILRB1 and LILRB2 that enhance innate and adaptive anti-cancer immune responses

Abstract Presentation Number: 6376

Session Category/Title: Immunology/Immune Checkpoints

Location/Poster Board#: Section 23 / 20

Session Date and Time: Wednesday Apr 19, 2023, 9:00 AM – 12:30 PM

"We are pleased to provide our first presentation of preclinical data regarding our dual targeting antibodies for LILRB1 and LILRB2 at the upcoming AACR (Free AACR Whitepaper) conference," said Kamal Puri, PhD, Chief Scientific Officer of OncoResponse. "The presentation will detail both our discovery and preclinical characterization efforts."